Cerner Enviza, 2800 Rock Creek Pkwy, North Kansas City, MO, 64117, USA.
Breast Cancer Res Treat. 2022 Oct;195(3):441-451. doi: 10.1007/s10549-022-06709-x. Epub 2022 Aug 20.
To report the treatment utilization patterns for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer in urban mainland China (CancerMPact®).
The results presented are from an online survey conducted in September 2019 with 45 physicians treating breast cancer patients from 11 cities in mainland China.
Surveyed physicians reported that Stage I HR+/HER2(-) breast cancer patients are often treated with surgery alone (42%), whereas the use of surgery in combination with systemic therapy with or without radiotherapy increases in later stages (Stage II 67%, Stage III 77%). Doxorubicin-cyclophosphamide (AC)-based regimens were the most common in both the neoadjuvant and adjuvant settings in HR+/HER2(-) breast cancer patients, across all stages. In metastatic patients, use of surgery and radiotherapy decreases in favor of utilization of systemic therapy alone. Pre- and post-menopausal metastatic patients were frequently treated with hormone therapy or AC-based regimens in first line. Regardless of the first-line therapy administered, capecitabine-based regimens were commonly used in second line. In third line, chemotherapy regimens containing capecitabine or gemcitabine were given to nearly 40% of HR+/HER2(-) breast cancer patients. There were no standard of care regimens established for fourth or greater lines of treatment. In metastatic HR+/HER2(-) breast cancer, physicians reported 50% objective response rates in first-line settings with a progression-free survival of 16 months.
HR+/HER2(-) breast cancer patients in urban mainland China were prescribed chemotherapy regimens more frequently than CDK4/6 inhibitors. Treatment practices varied, with physicians reporting the use of multiple modalities and treatment regimens for their patients.
报告中国大陆城市中激素受体阳性（HR+）/人表皮生长因子受体 2 阴性（HER2-）乳腺癌的治疗利用模式（CancerMPact®）。
本研究结果来自于 2019 年 9 月开展的一项在线调查，调查对象为来自中国大陆 11 个城市的 45 名治疗乳腺癌患者的医生。
调查医生报告称，I 期 HR+/HER2(-) 乳腺癌患者常单独接受手术治疗（42%），而在较晚期（II 期 67%，III 期 77%）则增加手术联合系统治疗且有或无放疗。蒽环类药物联合环磷酰胺（AC）方案在 HR+/HER2(-) 乳腺癌患者的新辅助和辅助治疗中均最为常用，且适用于各分期。在转移性患者中，手术和放疗的应用减少，而单独采用系统治疗的情况增多。绝经前和绝经后转移性患者在一线治疗中常采用激素治疗或 AC 方案。无论一线治疗方案如何，二线治疗中常采用卡培他滨方案。三线治疗中，近 40%的 HR+/HER2(-) 乳腺癌患者接受含卡培他滨或吉西他滨的化疗方案。对于四线或以上治疗，尚无标准治疗方案。在转移性 HR+/HER2(-) 乳腺癌中，一线治疗的客观缓解率为 50%，无进展生存期为 16 个月。
中国大陆城市中的 HR+/HER2(-) 乳腺癌患者接受化疗方案治疗的频率高于 CDK4/6 抑制剂。治疗实践存在差异，医生报告称其采用多种方式和治疗方案为患者治疗。
